Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 5

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

A Novel Class of Complement 3a Receptor Agonists and Antagonists Derived from the TLQP-21 Peptide

Rodriguez, Pedro, Pallais, Jean Pierre, He, Rongjun, Razzoli, Maria, McKee, John L., Bock, Hailey A., McCorvy, John D., Sham, Yuk Y., DiMarchi, Richard, Bartolomucci, Alessandro · 2025 · Journal of Medicinal Chemistry

Abstract

The complement 3a receptor (C3aR) is a G-protein-coupled receptor (GPCR) involved in inflammatory, metabolic, and neurological diseases. Two endogenous ligands (C3a and TLQP-21) and small molecules (SB290157 and JR14a) differentially signal at C3aR, but these properties are not fully understood and need to be optimized with medicinal chemistry. Here, we generated rationally designed peptidergic analogues of TLQP-21 in an effort to extend the range of compounds with therapeutic potential beyond C3a-derived peptidergic agonists or small-molecule antagonists. We identified key arginines in the central portion of the peptide and the C-terminus, where mutation confers enhanced plasma stability. Mutations at the C-terminal motif alanine–arginine (-AlaArg), with unnatural amino acids and stereoisomers conferred signaling selectivity, enhanced peptide potency (e.g., DArg10_DAla20), or resulted in a functional antagonist (DArg10_Aib20). Overall, we increased our understanding of the C3aR mechanism of action, expanding and differentiating the range of therapeutic potentials for this GPCR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.5c01177

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Research works printed but not linked: 61

  1. Kobilka, 2007, Protein Coupled Receptor Structure and Activation, Biochim. Biophys. Acta, 1768, 794, 10.1016/j.bbamem.2006.10.021 · DOI · Paper page
  2. Rosenbaum, 2009, The Structure and Function of G-Protein-Coupled Receptors, Nature, 459, 356, 10.1038/nature08144 · DOI · Paper page
  3. Hauser, 2017, Trends in GPCR Drug Discovery: New Agents, Targets and Indications, Nat. Rev. Drug Discov, 16, 829, 10.1038/nrd.2017.178 · DOI · Paper page
  4. Lagerström, 2008, Structural Diversity of G Protein-Coupled Receptors and Significance for Drug Discovery, Nat. Rev. Drug Discov., 7, 339, 10.1038/nrd2518 · DOI · Paper page
  5. Sahu, 2021, The Molecular Identity of the TLQP-21 Peptide Receptor, Cell. Mol. Life Sci., 78, 7133, 10.1007/s00018-021-03944-1 · DOI · Paper page
  6. Sarma, 2011, The Complement System, Cell Tissue Res., 343, 227, 10.1007/s00441-010-1034-0 · DOI · Paper page
  7. Cero, 2017, The Neuropeptide TLQP-21 Opposes Obesity via C3aR1-Mediated Enhancement of Adrenergic-Induced Lipolysis, Mol. Metabol., 6, 148, 10.1016/j.molmet.2016.10.005 · DOI · Paper page
  8. Stephens, 2012, A VGF-Derived Peptide Attenuates Development of Type 2 Diabetes via Enhancement of Islet β-Cell Survival and Function, Cell Metab., 16, 33, 10.1016/j.cmet.2012.05.011 · DOI · Paper page
  9. Brust, 2015, Gαi/o-Coupled Receptor-Mediated Sensitization of Adenylyl Cyclase: 40 Years Later, Eur. J. Pharmacol., 763, 223, 10.1016/j.ejphar.2015.05.014 · DOI
  10. Sahu, 2019, Peptide/Receptor Co-Evolution Explains the Lipolytic Function of the Neuropeptide TLQP-21, Cell Rep., 28, 2567, 10.1016/j.celrep.2019.07.101 · DOI · Paper page
  11. Pasupuleti, 2007, Preservation of Antimicrobial Properties of Complement Peptide C3a, from Invertebrates to Humans, J. Biol. Chem., 282, 2520, 10.1074/jbc.M607848200 · DOI
  12. Quell, 2017, Monitoring C3aR Expression Using a Floxed tdTomato-C3aR Reporter Knock-in Mouse, J. Immunol., 199, 688, 10.4049/jimmunol.1700318 · DOI · Paper page
  13. Reid, 2013, Downsizing a Human Inflammatory Protein to a Small Molecule with Equal Potency and Functionality, Nat. Commun., 4, 2802, 10.1038/ncomms3802 · DOI
  14. Rizzi, 2008, The VGF-Derived Peptide TLQP-21: A New Modulatory Peptide for Inflammatory Pain, Neurosci. Lett., 441, 129, 10.1016/j.neulet.2008.06.018 · DOI
  15. Koc, 2021, Changes in VGF and C3aR1 Gene Expression in Human Adipose Tissue in Obesity, Mol. Biol. Rep., 48, 251, 10.1007/s11033-020-06043-9 · DOI · Paper page
  16. Bartolomucci, 2006, TLQP-21, a VGF-Derived Peptide, Increases Energy Expenditure and Prevents the Early Phase of Diet-Induced Obesity, Proc. Natl. Acad. Sci. U. S. A., 103, 14584, 10.1073/pnas.0606102103 · DOI · Paper page
  17. Possenti, 2012, Characterization of a Novel Peripheral Pro-Lipolytic Mechanism in Mice: Role of VGF-Derived Peptide TLQP-21, Biochem. J., 441, 511, 10.1042/BJ20111165 · DOI · Paper page
  18. Rodriguez, 2024, Functional Profiling of the G Protein-Coupled Receptor C3aR1 Reveals Ligand-Mediated Biased Agonism, J. Biol. Chem., 300, 105549, 10.1016/j.jbc.2023.105549 · DOI · Paper page
  19. Gao, 2020, The Complement C3a and C3a Receptor Pathway in Kidney Diseases, Front. Immunol., 11, 1875, 10.3389/fimmu.2020.01875 · DOI
  20. Hugli, 1977, Synthetic Peptides with the Biological Activities and Specificity of Human C3a Anaphylatoxin, Proc. Natl. Acad. Sci. U. S. A., 74, 1826, 10.1073/pnas.74.5.1826 · DOI · Paper page
  21. Morganroth, 1990, C3a57–77, a C-Terminal Peptide, Causes Thromboxane-Dependent Pulmonary Vascular Constriction in Isolated Perfused Rat Lungs, Am. Rev. Respir. Dis., 141, 296, 10.1164/ajrccm/141.2.296 · DOI
  22. Scully, 2010, Selective Hexapeptide Agonists and Antagonists for Human Complement C3a Receptor, J. Med. Chem., 53, 4938, 10.1021/jm1003705 · doi:10.1021/jm1003705
  23. Denonne, 2007, Discovery of New C3aR Ligands. Part 2: Amino-Piperidine Derivatives, Bioorg. Med. Chem. Lett., 17, 3262, 10.1016/j.bmcl.2007.04.023 · doi:10.1016/j.bmcl.2007.04.023
  24. Reid, 2014, Potent Heterocyclic Ligands for Human Complement C3a Receptor, J. Med. Chem., 57, 8459, 10.1021/jm500956p · DOI
  25. Ames, 2001, Identification of a Selective Nonpeptide Antagonist of the Anaphylatoxin C3a Receptor That Demonstrates Antiinflammatory Activity in Animal Models, J. Immunol., 166, 6341, 10.4049/jimmunol.166.10.6341 · DOI · Paper page
  26. Rowley, 2020, Potent Thiophene Antagonists of Human Complement C3a Receptor with Anti-Inflammatory Activity, J. Med. Chem., 63, 529, 10.1021/acs.jmedchem.9b00927 · DOI
  27. Alexander, 2021, THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G Protein-Coupled Receptors, Br. J. Pharmacol., 178, S27, 10.1111/bph.15538 · DOI · Paper page
  28. Mathieu, 2005, The C3a Receptor Antagonist SB 290157 Has Agonist Activity, Immunol. Lett., 100, 139, 10.1016/j.imlet.2005.03.003 · DOI
  29. Luo, 2025, Structural Insights into the Agonist Activity of the Nonpeptide Modulator JR14a on C3aR, Cell Discov., 11, 7, 10.1038/s41421-024-00765-x · DOI
  30. Masin, 2015, 6─Bordetella Protein Toxins, 161, 10.1016/B978-0-12-800188-2.00006-9 · DOI
  31. Mangmool, 2011, Gi/o Protein-Dependent and -Independent Actions of Pertussis Toxin (PTX), Toxins, 3, 884, 10.3390/toxins3070884 · DOI · Paper page
  32. Leaney, 2000, The Role of Members of the Pertussis Toxin-Sensitive Family of G Proteins in Coupling Receptors to the Activation of the G Protein-Gated Inwardly Rectifying Potassium Channel, Proc. Natl. Acad. Sci. U. S. A., 97, 5651, 10.1073/pnas.080572297 · DOI
  33. Beautrait, 2017, A New Inhibitor of the β-Arrestin/AP2 Endocytic Complex Reveals Interplay between GPCR Internalization and Signalling, Nat. Commun., 8, 15054, 10.1038/ncomms15054 · DOI · Paper page
  34. Sundqvist, 2020, Barbadin Selectively Modulates FPR2-Mediated Neutrophil Functions Independent of Receptor Endocytosis, Biochim. Biophys. Acta, Mol. Cell Res., 1867, 118849, 10.1016/j.bbamcr.2020.118849 · DOI
  35. He, 2021, Barbadin Potentiates Long-Term Effects of Lorcaserin on POMC Neurons and Weight Loss, J. Neurosci., 41, 5734, 10.1523/JNEUROSCI.3210-20.2021 · DOI
  36. Roberts, 2009, Metabolic Phenotyping of a Model of Adipocyte Differentiation, Physiol. Genomics, 39, 109, 10.1152/physiolgenomics.90365.2008 · DOI
  37. Malina, 2005, Conjugation of Fatty Acids with Different Lengths Modulates the Antibacterial and Antifungal Activity of a Cationic Biologically Inactive Peptide, Biochem. J., 390, 695, 10.1042/BJ20050520 · DOI · Paper page
  38. Storck, 2020, Fatty Acid Conjugation Leads to Length-Dependent Antimicrobial Activity of a Synthetic Antibacterial Peptide (Pep19–4LF), Antibiotics (Basel), 9, 844, 10.3390/antibiotics9120844 · doi:10.3390/antibiotics9120844
  39. Polyethylene Glycol─an overview|ScienceDirect Topics. https://www.sciencedirect.com/topics/neuroscience/polyethylene-glycol (accessed June 06, 2023).
  40. Suk, 2016, PEGylation as a Strategy for Improving Nanoparticle-Based Drug and Gene Delivery, Adv. Drug Deliv. Rev., 99, 28, 10.1016/j.addr.2015.09.012 · DOI · Paper page
  41. Chao, 1999, Role of the Second Extracellular Loop of Human C3a Receptor in Agonist Binding and Receptor Function, J. Biol. Chem., 274, 9721, 10.1074/jbc.274.14.9721 · DOI
  42. Li, 2021, The “C3aR Antagonist” SB290157 Is a Partial C5aR2 Agonist, Front. Pharmacol., 11, 591398, 10.3389/fphar.2020.591398 · DOI
  43. Wang, 2023, Revealing the Signaling of Complement Receptors C3aR and C5aR1 by Anaphylatoxins, Nat. Chem. Biol., 19, 1351, 10.1038/s41589-023-01339-w · DOI
  44. Doolen, 2017, Complement 3a Receptor in Dorsal Horn Microglia Mediates Pronociceptive Neuropeptide Signaling, Glia, 65, 1976, 10.1002/glia.23208 · DOI · Paper page
  45. Cho, 2020, TLQP-21 Mediated Activation of Microglial BV2 Cells Promotes Clearance of Extracellular Fibril Amyloid-β, Biochem. Biophys. Res. Commun., 524, 764, 10.1016/j.bbrc.2020.01.111 · DOI
  46. Rivolta, 2017, JMV5656, A Novel Derivative of TLQP-21, Triggers the Activation of a Calcium-Dependent Potassium Outward Current in Microglial Cells, Front. Cell. Neurosci., 11, 41, 10.3389/fncel.2017.00041 · DOI
  47. Coulthard, 2015, Is the Complement Activation Product C3a a Proinflammatory Molecule? Re-Evaluating the Evidence and the Myth, J. Immunol., 194, 3542, 10.4049/jimmunol.1403068 · DOI · Paper page
  48. Reid, 2013, Downsizing a Human Inflammatory Protein to a Small Molecule with Equal Potency and Functionality, Nat. Commun., 4, 2802, 10.1038/ncomms3802 · DOI
  49. Klos, 2013, International Union of Basic and Clinical Pharmacology. [Corrected]. LXXXVII. Complement Peptide C5a, C4a, and C3a Receptors, Pharmacol. Rev., 65, 500, 10.1124/pr.111.005223 · DOI · Paper page
  50. Li, 2008, Cyclic AMP Plays a Critical Role in C3a-Receptor Mediated Regulation of Dendritic Cells in Antigen Uptake and T-Cell Stimulation, Blood, 112, 5084, 10.1182/blood-2008-05-156646 · DOI
  51. Stephens, 2012, A VGF-Derived Peptide Attenuates Development of Type 2 Diabetes via Enhancement of Islet β-Cell Survival and Function, Cell Metab., 16, 33, 10.1016/j.cmet.2012.05.011 · DOI · Paper page
  52. Fargali, 2014, The Granin VGF Promotes Genesis of Secretory Vesicles, and Regulates Circulating Catecholamine Levels and Blood Pressure, FASEB J., 28, 2120, 10.1096/fj.13-239509 · DOI · Paper page
  53. El Gaamouch, 2020, VGF-Derived Peptide TLQP-21 Modulates Microglial Function through C3aR1 Signaling Pathways and Reduces Neuropathology in 5xFAD Mice, Mol. Neurodegener., 15, 4, 10.1186/s13024-020-0357-x · DOI · Paper page
  54. Ahmad, 2022, Abstract 15: The Novel Complement C3ar Antagonist Jr14a Is Neuroprotective In Stroke, Stroke, 53, A15, 10.1161/str.53.suppl_1.15 · DOI
  55. Ahmad, 2020, C3a Receptor Antagonist Therapy Is Protective with or without Thrombolysis in Murine Thromboembolic Stroke, Br. J. Pharmacol., 177, 2466, 10.1111/bph.14989 · DOI
  56. Ahmad, 2019, C3a Receptor Inhibition Protects Brain Endothelial Cells Against Oxygen-Glucose Deprivation/Reperfusion, Exp. Neurobiol., 28, 216, 10.5607/en.2019.28.2.216 · DOI
  57. Ishii, 2021, Mitochondrial C3a Receptor Activation in Oxidatively Stressed Epithelial Cells Reduces Mitochondrial Respiration and Metabolism, Front. Immunol., 12, 628062, 10.3389/fimmu.2021.628062 · DOI
  58. Vibhuti, 2011, Distinct and Shared Roles of β-Arrestin-1 and β-Arrestin-2 on the Regulation of C3a Receptor Signaling in Human Mast Cells, PLoS One, 6, 10.1371/journal.pone.0019585 · doi:10.1371/journal.pone.0019585
  59. Yadav, 2023, Molecular Basis of Anaphylatoxin Binding, Activation, and Signaling Bias at Complement Receptors, Cell, 186, 4956, 10.1016/j.cell.2023.09.020 · DOI
  60. Kim, 2025, Structural Insights into Small-Molecule Agonist Recognition and Activation of Complement Receptor C3aR, EMBO J., 44, 2803, 10.1038/s44318-025-00429-w · DOI
  61. Blasi, 1990, Immortalization of Murine Microglial Cells by a V-Raf/v-Myc Carrying Retrovirus, J. Neuroimmunol, 27, 229, 10.1016/0165-5728(90)90073-V · DOI · Paper page

Cited by

See all 5

Metadata

Authors
Rodriguez, P., Pallais, J. P., He, R., Razzoli, M., McKee, J. L., Bock, H. A., McCorvy, J. D., Sham, Y. Y., DiMarchi, R., & Bartolomucci, A.
Venue
Journal of Medicinal Chemistry
Published
2025-09-03
Volume
68
Issue
18
Pages
19107-19121
ISSN
  • 0022-2623
  • 1520-4804
Cited by
5
References
7
Language
en
Funders
  • National Institute of Mental Health (75N95023C00021)
  • National Institute of General Medical Sciences (R35 GM133421)
  • National Institute of Diabetes and Digestive and Kidney Diseases (T32 DK083250)
  • Clinical and Translational Science Institute, University of Minnesota (NA)
  • Institute for Diabetes, Obesity and Metabolism, University of Minnesota (NA)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Novel Class of Complement 3a Receptor Agonists and Antagonists Derived from the TLQP-21 Peptide. https://app.cochat.ai/papers/10.1021/acs.jmedchem.5c01177
The paper
Rodriguez, P., Pallais, J. P., He, R., Razzoli, M., McKee, J. L., Bock, H. A., McCorvy, J. D., Sham, Y. Y., DiMarchi, R., & Bartolomucci, A. (2025). A Novel Class of Complement 3a Receptor Agonists and Antagonists Derived from the TLQP-21 Peptide. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01177

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.